While rituximab has dramatically improved outcomes for patients with CD20
Introduction
Development of anti-CD20 monoclonal antibodies (mAbs) can be traced back to 1979, when the CD20 antigen (then called B1) was identified (Stashenko et al, 1980; Nadler et al, 1981) . Technical advancements enabled mass production of a chimeric mAb with clinical activity targeting the human CD20 antigen and impressive activity was seen in patients with B cell malignancies (Miller et al, 1982; Maloney et al, 1994; McLaughlin et al, 1998) . Rituximab was first approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL) on 26 November 1997. Over two decades later, rituximab has demonstrated impressive clinical activity across the majority of B cell neoplasms: as a single agent, in combination with chemotherapy or in the maintenance setting . As our understanding of its mechanism of action evolved, the concept of "rituximab resistance" also emerged and theories were generated on how this resistance could be optimally overcome (Cartron et al, 2011) .
Obinutuzumab, a new generation anti-CD20 antibody was designed in an attempt to overcome several postulated mechanisms of resistance. The parental antibody for obinutuzumab was chosen because of its "type II" properties -its ability to cause homotypic adhesion and employ a different mechanism of direct cell death (DCD) (M€ ossner et al, 2010; Niederfellner et al, 2011) . In addition, by manufacturing this type II antibody in cell lines with overexpression of glycosylation enzymes, the resultant antibody has non-fucosylated sugars on the Fc portion, with the potential to generate a more potent effector response in the recipient.
In vitro and preclinical studies of obinutuzumab suggested superior activity when compared to rituximab and other Type I mAbs (M€ ossner et al, 2010; Herter et al, 2013a,b) . Improvements in progression-free survival (PFS) have been demonstrated in clinical trials comparing both antibodies head-to-head, both in patients with treatment-na€ ıve chronic lymphocytic leukaemia (CLL) and co-morbidities and untreated symptomatic follicular lymphoma (FL) (Goede et al, 2014; Marcus et al, 2017) . However, recent results from a large phase 3 trial involving patients with untreated diffuse large B cell lymphoma (DLBCL) demonstrated no advantage . This review will interrogate the available datapreclinical and clinical -and discuss the potential reasons for these contradictory results. The role of obinutuzumab moving forward across the B cell lymphoproliferative disorders will also be evaluated.
Mechanism of action: does type matter?
The CD20 molecule is universally expressed by normal B cells in all stages of development, from the pre-B cell up to the mature plasma cell as well as by most B cell malignancies (Stashenko et al, 1980; Anderson et al, 1984) . Despite extensive study, the true role of CD20 remains poorly understood. It has no natural ligand but is thought to possibly play a role in calcium ion influx (Walshe et al, 2008) . It is widely expressed on the cell surface and is not immediately internalized upon antibody binding (Press et al, 1987; . Thus mAbs directed towards CD20 cannot depend on the delivery of a cytotoxic moiety into the cell, but rather the consequences of binding the CD20 antigen and recruitment of a host response to the opsonized cell.
Since a classification system for anti-CD20 mAbs was first described Cragg & Glennie, 2004) , much emphasis has been placed on the fact that rituximab is a Type I antibody and obinutuzumab is a Type II antibody (Illidge et al, 2015) . The key differences that are proposed to exist between these two antibodies are outlined in Table I and Fig 1. In brief, rituximab relocalizes CD20 to lipid rafts and appears to evoke minimal DCD but induces significant complement-dependent cytotoxicity (CDC) and antibodydependent cellular cytotoxicity (ADCC). In contrast, obinutuzumab does not induce CDC, but, by virtue of alternative binding to the CD20 molecule, can evoke greater DCD, chiefly by mechanisms that are largely caspase-independent. The afucosylated Fc portion appears to confer more potent induction of ADCC and antibody-dependent phagocytosis (ADP) than rituximab (M€ ossner et al, 2010; Herter et al, 2013a; Elias et al, 2017) . Why are these differences potentially relevant? It was thought that the ability of type I anti-CD20 mAbs to activate CDC might have limited efficacy in vivo, due to the expression of complement-resistance factors on target cells and the potential for complement protein exhaustion (Cartron et al, 2004; M€ ossner et al, 2010) .Thus, engineering out this property was thought unlikely to prove detrimental. Enhancing DCD by mechanisms independent of caspase activation was certainly thought to be desirable, especially in those B cell disorders with upregulation of antiapoptotic proteins that inhibit this suicidal pathway. Finally, by reducing the fucose content of the Fc portion, it was hoped that obinutuzumab could overcome the low affinity of certain polymorphisms of the FcGamma receptor 3A (FCGR3A) on effector cells, hence improving ADCC and ADP in a greater proportion of patients (Center for Drug Evaluation and Research 2013; Golay et al, 2013; Herter et al, 2013a; Laprevotte et al, 2013; Rafiq et al, 2013; Terszowski et al, 2014) .
The concept of rituximab resistance
Despite being one of the most effective and widely used therapeutic mAbs developed to date, the effectiveness of rituximab is limited by inter-individual variability and the development of resistance. Rituximab resistance has been somewhat arbitrarily defined but is generally accepted as a lack of response or overt progression during, or within 6 months of completion of a rituximab-containing regimen. Summarized data from rituximab monotherapy trials suggest an incidence of rituximab resistance in treatment-na€ ıve indolent NHL at 30-60% (Rezvani & Maloney, 2011) but this is probably overestimating the true incidence for a combination approach. Chemo sensitization and other mechanisms of Chan et al (2003) No homotypic adhesion synergy improve responses, thus decreasing the likely incidence of rituximab resistance (Demidem et al, 1997; Alas et al, 2002; Jazirehi et al, 2005; Hayashi et al, 2016) . In patients with FL treated in the modern era with immunochemotherapy, rituximab resistance (based on the above definition) was found in 16.7%, although it is impossible to separate the relative contribution of rituximab versus chemotherapy in combination approaches (Mozessohn et al, 2011) . As an immunotherapy, rituximab relies to a significant degree on the host to maximally evoke its cytotoxic effects. Thus, potential sources of resistance are many and may be tumour-or host-related (Fig 2) . Despite universal expression of the CD20 antigen, different B cell lymphoproliferative neoplasms exhibit variable responses to the administration of rituximab. The density of CD20 expression varies between entities; CLL cells have been consistently found to express less CD20 on their surface than other B cell lymphomas, and was initially blamed for the poor responses to rituximab monotherapy seen in CLL (Almasri et al, 1992; Prevodnik et al, 2011) . Although mutations of the CD20 epitope do not appear to be an important mechanism of resistance (Johnson et al, 2009) reductions in the density of expression can occur, with CLL and mantle cell lymphoma (MCL) cells expressing less CD20 than FL or DLBCL cells after exposure to the antibody Hiraga et al, 2009; Beers et al, 2010; Prevodnik et al, 2011) . Decreased expression of CD20 may also result from trogocytosis as opposed to downregulation or significant internalization (Elias et al, 2017) . From the Greek word meaning to gnaw or nibble, the phenomenon of trogocytosis has been described to occur as opsonized CD20-coated tumour cells encounter FcgammaR-bearing effector cellsmonocytes, natural killer (NK) cells and neutrophils. An immunological synapse is formed and, instead of being phagocytized, the antibody-antigen complex is removed and internalized (along with a portion of membrane) by the effector cell, leaving the targeted malignant B cell intact and alive. This has also been referred to as a "shaving reaction" and serves to modify the efficacy of therapeutic mAbs, modifying both the immune response and inherent B cell function Taylor & Lindorfer, 2015; Skopelja-Gardner et al, 2017; Valgardsdottir et al, 2017) . Malignant B cells may acquire resistance to apoptosis, in particular that which is caspase-dependent: decreased BAX and BAK have been reported in cell lines repeatedly exposed to rituximab .
The ability of effector cells to recognize the Fc portion of the mAb bound to the malignant clone and kill or phagocytize it is crucial (Beers et al, 2010; Taylor & Lindorfer, 2010; Du et al, 2014) . Polymorphisms in FCGR3A at position 158 can enhance (valine) or reduce (phenylalanine) the affinity of this receptor for the Fc portion of the antibody, with associated impact on B cell depletion with this agent as a result (Cartron et al, 2002; Weng & Levy, 2003; Hatjiharissi et al, 2007; Weng et al, 2007) . Studies on ADCC induced by rituximab have centred on the predominant role of natural killer (NK) cells in particular, as~90% of NK cells in circulation in the peripheral blood express CD16, the FCGR3A (Nagler et al, 1989) . However, NK cells also co-express a wide array of other receptors with activating or inhibitory functions that can influence their ability to elicit ADCC. Inhibitory killer cell immunoglobulin-like receptors (KIRs) interact with public epitopes on human leucocyte antigen (HLA) and are involved in the natural regulation of NK cells. This inhibitory mechanism can interfere with the ability of unlicensed NK cells to cause ADCC upon encountering a rituximab opsonized cell (Binyamin et al, 2008; Terszowski et al, 2014) . It would seem intuitive that an exhausted cohort of effector cells in the host could also play a role in rituximab resistance, at least to those mechanisms requiring an immune response (Bowles & Weiner, 2005; Vire et al, 2009; Beurskens et al, 2012; Danielou-Lazareth et al, 2013) .
Complement activation due to the binding of C1q by rituximab is a key component of its activity (Reff et al, 1994) . However, C1q binding to the Fc region of the antibody interferes with the ability of effector cells to interact with the Fc portion, potentially decreasing ADCC (Wang et al, 2008) . Up-regulation of the complement inhibitory molecules, CD55 and CD59, has been linked to the development of rituximab resistance and restoration of CDC has been observed upon blocking this mechanism (Golay et al, 2000 (Golay et al, , 2001 Bannerji et al, 2003; Takei et al, 2006; Ge et al, 2011) . Consumption of complement proteins themselves can also hamper CDC and replenishing them can restore or enhance activity (Kennedy et al, 2004; Xu et al, 2011) .
Obinutuzumab was designed to overcome several described mechanisms of rituximab resistance (M€ ossner et al, 2010) . It binds to an overlapping epitope of CD20, but in a different orientation, and the modified hinge region resulted in increased pro-apoptotic potential (Niederfellner et al, 2011; Klein et al, 2013; Konitzer et al, 2015) . In vitro evaluation suggested it was capable of inducing non-caspase dependent DCD and increased levels of BAX and BAK, overcoming resistance to apoptosis (Alduaij et al, 2011; Illidge et al, 2014) . With virtually absent CDC, the negative influence of complement-inhibitory molecules and complement protein exhaustion would no longer prove detrimental (Wang et al, 2008; M€ ossner et al, 2010; Herter et al, 2013a; Rafiq et al, 2013) . Finally, the afucosylated Fc portion demonstrated enhanced in vitro ADCC and ADP, overcoming the negative effect of inhibitory KIR receptors on NK cells and the low affinity polymorphisms of the FCGR3A (Cartron et al, 2002; Weng & Levy, 2003; Golay et al, 2013; Herter et al, 2013a; Laprevotte et al, 2013; Rafiq et al, 2013; Terszowski et al, 2014) .
Rituximab versus obinutuzumab -the dose controversy
The first approved schedule for rituximab, 375 mg/m 2 intravenously weekly for 4 weeks, was established as a result of drug availability rather than dedicated dose finding studies Grillo-Lopez, 2000) . . After a dose-response relationship was described by investigators evaluating rituximab monotherapy in patients with CLL, a higher dose of 500 mg/m 2 was adopted (O'Brien et al,
2001
; Li et al, 2012) . For DLBCL, despite suggestions that, for older male patients in particular, 375 mg/m 2 might be inadequate, escalation trials did not yield statistically superior results when compared to historical data (Muller et al, 2012; Murawski et al, 2014; Pfreundschuh et al, 2014b ). An attempt was made to model the pharmacokinetics (PK) of rituximab to determine the dose required for maximal effect, incorporating the possible influence of the FcGamma receptor polymorphisms (Ternant et al, 2009) . The model suggested that higher (750 mg/m 2 ) or prolonged (375 mg/m 2 every 2 months for 2 years) doses of rituximab should be associated with improved PFS. However, the model was based on data obtained from patients with FL only and 375 mg/m 2 but no higher dose levels and the authors agreed the results needed to be interpreted with caution.
Other groups have argued that less might be more. As little as 20 mg/m 2 (almost 20-fold less than the standard dose used) delivered to CLL patients thrice weekly was found to result in less trogocytosis of CD20, less consumption of complement and maintenance of effective B cell depletion . While desirable, the identification of a universal serum level that correlates with optimal therapeutic activity may be unrealistic. Similar to other mAbs, empiric doses lead to a wide range of serum rituximab levels in individual patients (Berinstein et al, 1998; Ng et al, 2005) . It was observed in the early studies that indolent NHL (iNHL) patients achieving serum trough (C trough ) levels in excess of 25 lg/l had better responses (Berinstein et al, 1998) . However, lower C trough levels may be more indicative of a large or unresponsive tumour burden than suboptimal dosing (Jager et al, 2012) . In spite of the endeavours outlined, the originally approved dose of 375 mg/m 2 has remained the standard, whether rituximab is administered alone, in combination with chemotherapy or as maintenance (with the exception of CLL, as mentioned).
In preclinical evaluation comparing obinutuzumab directly to rituximab, improvements in DCD, ADCC and lymphocyte depletion were observed with obinutuzumab when identical concentrations of both agents were used. In vitro, further increases in the concentration of rituximab appeared to be associated with a plateau in efficacy, which was not observed for obinutuzumab (M€ ossner et al, 2010; Herter et al, 2013a; Rafiq et al, 2013) . Furthermore, at saturating antibody concentrations, obinutuzumab bound to B cells at levels approximately half those of rituximab (M€ ossner et al, 2010) .
In a semi-mechanistic PK/pharmacodynamics (PD) model recently presented in abstract form, drug removal due to drug-target binding was 4.3-fold lower for obinutuzumab compared with rituximab (0.0642 vs. 0.274/nmol/l 9 per day, P < 0.01), cell-kill coefficient for obinutuzumab was 4.7-fold greater than that for rituximab (0.851 vs. 0.182/day, P < 0.01), and the half-maximal effective concentration of obinutuzumab was 15-fold lower (64.5 vs. 962 nmol/l, P < 0.01) (Kamisoglu et al, 2017) . Taken together, these data suggest that, for an equal antigenic mass, less obinutuzumab is necessary to evoke cytotoxicity and less is taken up by the antigenic "sink" of the tumour -leaving more drug available to either bind elsewhere (or continue to circulate) when compared with rituximab.
The dose of obinutuzumab selected for Phase III evaluation was based on modelling of pooled PK data from patients with relapsed/refractory CD20 + iNHL. Data on a small number of aggressive B cell NHL patients was also included . On the basis of a doseresponse relationship described in those with iNHL that were treated with the higher doses of 1600 mg/800 mg, comparable toxicity and preference for the simplicity of a fixed-dose regimen, a flat dose of 1000 mg was selected. Administration on days 1, 8 and 15 during cycle 1, then day 1 thereafter for each 21-day cycle resulted in similar serum trough concentrations to those generated by the 1600/800 mg doses when this was modelled. Of note, no dose-response relationship was seen in the patients with aggressive histology lymphoma included in this PK/PD model. As summarized in Table II , the selected schedule of obinutuzumab would appear to result in the administration of more antibody, which is of similar molecular weight to rituximab. If dose does matter, this certainly confers an advantage to obinutuzumab. However, as discussed above, it might be the case that rituximab has a dose-related ceiling of efficacy and could be more heavily influenced by tumour burden than obinutuzumab.
From bench to bedside -results from comparative clinical trials
After promising activity was demonstrated in single-arm studies involving patients with relapsed and refractory CD20-positive B cell malignancies (Salles et al, 2012 (Salles et al, , 2013 Sehn et al, 2012) , obinutuzumab has been compared head-to-head with rituximab across a variety of clinical settings.
The first direct comparison between rituximab and obinutuzumab was within a randomized phase II trial (GAUSS) involving 175 patients with relapsed indolent iNHL . Patients received either 4 weekly doses of rituximab (375 mg/m 2 ) or obinutuzumab (1000 mg/week 9 4 doses) and those without disease progression were eligible to receive maintenance therapy with the same dose every 2 months for up to 2 years. Eligible patients needed to have received at least one prior rituximab-containing regimen with a documented response lasting ≥6 months -thus these patients were not, by definition, resistant to rituximab. The majority of patients enrolled had FL (N = 149). It was estimated that a sample size of 70 patients with FL in each arm would be required to have an 80% power to pick up a 15% difference between overall response rates (ORR) when the alpha was 0.2, however only a one-sided v 2 was used.
Investigator-assessed ORR favoured obinutuzumab, 44.6% vs. 33.3% with a P-value of 0.08 (less than the study's predetermined threshold of 0.2 for significance) . Interestingly, obinutuzumab appeared to induce deeper remissions, with an almost two-fold higher complete response rate (CR+CRu 41.9% vs. 22.7%; P = 0.006). Although this trial was not powered to assess PFS, there was no apparent difference in PFS between the agents (Fig 3A) .
More recently, results in the upfront setting have been published on 1202 treatment-na€ ıve FL patients . GALLIUM, an open-label phase III study, randomized symptomatic advanced stage patients to either obinutuzumab or rituximab combined with chemotherapy (G-chemo and R-chemo, respectively). The chemotherapy backbone [CVP (cyclophosphamide, vincristine, prednisolone) , CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or bendamustine] was administered according to site selection, with the majority of sites (57.1%) choosing bendamustine. Responders at the end of induction could receive maintenance therapy with the assigned antibody administered every 2 months for a total of 2 years. Median patient age was 59 years (range: 23-88 years), thus the study population was somewhat younger than might be expected outside of a trial setting, and the primary endpoint was investigator-assessed PFS. A planned interim analysis was performed after a median follow-up of 34.5 months, resulting in an estimated 3-year PFS of 80% for G-chemo versus 73.3% for R-chemo, with a hazard ratio (HR) of 0.66; 95% confidence interval (CI), 0.51-0.85; P = 0.001 (Fig 3B) . At the end of induction therapy, response rates for G-chemo and R-chemo were similar -ORR 88.5% vs. 86.9% and CR 19.5% vs. 23.8% respectively. No differences were observed between arms in OS or in patient reported quality of life . In a subgroup analysis reported separately, involving 696 patients from this trial, G-chemo treated patients appeared more likely to become minimal residual disease (MRD) negative (MRD-) than those treated with Rchemo (92% vs. 85%; P = 0.0041), with associated improvement in PFS for those that became MRD- (Pott et al, 2016) . In addition, there did appear to be an apparent reduction in early progression events observed in the G-chemo arm of GALLIUM, with separation of the curves prior to 12 months and approximate 2-year PFS of 88% for G-chemo compared with 81% for those treated with R-chemo (Fig 3B) . This was confirmed in a recent updated analysis presented in abstract form, where early progression prior to 24 months (POD24) was associated with inferior outcomes -including survivaland G-chemo resulted in a relative risk reduction of 33.85 (12.76-49.84) of POD24 compared with R-chemo (Launonen et al, 2017) . In totality, whether this apparent improvement in depth of response, reduction in early events and overall 34% decrease in risk of progression or death is sufficient to merit a change to G-chemo upfront will need to be further evaluated by clinicians and payers.
For patients with previously untreated CLL and co-morbidities, the combination of obinutuzumab with chlorambucil (G-CLB) has been shown more effective than rituximab and chlorambucil (R-CLB). The open-label three-arm CLL-11 trial randomized 781 previously untreated CLL patients deemed unfit for fludarabine-based therapy, to receive chlorambucil (CLB) monotherapy, R-CLB or G-CLB in a 1:2:2 ratio (Goede et al, 2014) . The dose of rituximab was escalated after the first cycle, from 375 to 500 mg/m 2 and the schedule of obinutuzumab was as previously outlined (1000 mg days 1, 8 and 15 cycle 1; day 1 cycles 2-6). The trial population was certainly reflective of clinical practice, with a median age of enrolled patients of 73 years (39-88), median creatinine clearance of 62 ml/min and participants burdened with some degree of co-morbidity. When the two antibody-containing regimens were directly compared, obinutuzumab led to a statistically significant prolongation of median PFS, with a net gain of almost 14 months in the updated analysis compared to rituximab (Fig 3C) (Goede et al, 2015) . No benefit in overall survival (OS) has yet been demonstrated comparing G-CLB with R-CLB, but G-CLB conferred an OS survival advantage over CLB alone. No differences were observed in quality of life over time. G-CLB achieved a higher CR rate (20.7% vs. 7.0%) and greater proportion of patients achieving MRD negativity. Less than one-third of enrolled patients had evaluable samples for bone marrow MRD assessment, but 19.5% of those that did were MRD-at the end of treatment vs. 2.6% in the R-CLB arm. Similar results were GAUSS ( In aggressive lymphoma, the combination of obinutuzumab with the standard backbone of CHOP in previously untreated DLBCL was found to be no better than the current standard of care, R-CHOP (CHOP + rituximab) (Vitolo et al, 2016 . The large phase III GOYA trial randomized 1418 patients with DLBCL to receive 8 cycles of obinutuzumab (1000 mg on days 1, 8 and 15 cycle 1; day 1 cycles 2-8) or rituximab (375 mg/m 2 day 1 cycles 1-8) in combination with either 6 or 8 cycles of CHOP (pre-specified by site). After a median observation time of 29 months, there were no significant differences in the PFS, OR, CR rates or overall survival between the two arms, whether investigator or independent review committee assessed (Fig 3D) . The final analysis of the GAINED phase III trial (NCT01659099), which also directly compared R-chemo [ACVBP-14 (doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone, every 14 days) or CHOP-14 (CHOP every 14 days), according to local centre preference] to G-chemo in treatment-na€ ıve DLBCL patients, was also very recently presented (Casasnovas et al, 2017) . The investigators reported no advantage to G-chemo in this population. This trial was stopped after a planned third interim analysis demonstrated futility at a median duration of follow-up of 25.2 months (range: 24.28-26.2). At 2 years, there were no differences observed in either the stratified or unstratified event-free survival (EFS) estimates. Stratified estimates met bounds of futility (P = 0.1321, above the futility bound of 0.069) and reported unstratified estimates were 57% (95% CI; 51.5-62.2) for R-chemo treated patients compared with 60% (95% CI; 54.4-65.1) for patients treated with G-chemo (P = 0.1296; HR = 0.876; 95% CI; 0.694-1.105) (Casasnovas et al, 2017) .
SAFETY -same target, same toxicity?
After almost 2 decades of use, the safety profile of rituximab has been well established, with primary toxicities including infusion-related reactions (IRRs) and, less commonly, cytopenias and infection. Progressive multifocal leucoencephalopathy (PML) has been reported for both agents although it remains a very rare event (Raisch et al, 2016; Molloy et al, 2017) . Obinutuzumab has exhibited a similar safety profile, but in general has been associated with a higher incidence of adverse events. The incidence of severe IRRs (Grade ≥3) is at least double that observed for rituximab, some of which may relate to more pronounced cytokine release induced by this agent (Freeman et al, 2015) . Obinutuzumab also appears to be associated with higher rates of grade ≥3 neutropenia, but without significant increase in severe infections compared with rituximab. Additionally, more thrombocytopenia has been noted, which may also relate to cytokine-induced activation of the clotting cascade and up-regulation of endothelial adhesion molecules, although this is based on limited data and highly speculative (Xia et al, 1998; Mihara et al, 2012; Walter et al, 2016) . In the GALLIUM trial, G-chemo may have been associated with an increased risk of secondary malignancies (7.2% vs. 5%); in particular, all haematological cancers were seen in the obinutuzumab-treated group -N = 6 (1%) vs. N = 0 for Rchemo. Reported rates of selected adverse events from the previously described head-to-head trials are summarized in Table III .
Discussion
Deliberately engineered to overcome mechanisms of rituximab resistance, obinutuzumab has demonstrated improved efficacy over rituximab, at least in previously untreated CLL and co-morbidities and in untreated FL. However, despite significant advantage seen in pre-clinical analyses, these modifications have not translated into a universal benefit over rituximab when compared in head-to-head trials. How can this be explained? Key considerations may include the clinical context of its use, including differential benefit within histological subtypes or impact of host immune integrity. Based on its unique properties, it is tempting to suggest that the Table III . Selected adverse event rates reported in head-to-head clinical trials.
Clinical trial IRRs (all grades)
G-CLB 11% R-CLB 10% Goede et al (2014 GALLIUM (TN FL) primary advantage of obinutuzumab may be most apparent in the setting of innate or acquired rituximab resistance. In patients with previously untreated FL, the benefit observed in the GALLIUM trial may ultimately lead to a new standard of care, with obinutuzumab replacing rituximab as the anti-CD20 mAb of choice when combined with chemotherapy . Critics suggest that response rates were similar following induction and that the benefit observed may result from the higher doses of obinutuzumab used in the maintenance setting (Armitage & Longo, 2017) . Whether clinicians and payers will be willing to accept the additional cost of switching from rituximab, which could now include a subcutaneous preparation or biosimilar, for the conferred benefit achieved by obinutuzumab remains to be seen. It would seem that G-chemo can generate deep responses, with a greater proportion of patients achieving MRD negativity and also noteworthy is the significant reduction in early progressions at 24 months compared with those treated with R-chemo (Launonen et al, 2017) . If this were the case, obinutuzumab could improve outcomes for the highest risk, early-progressing population that has been well described in the rituximab era (Casulo et al, 2015) . The survival advantage demonstrated in the GADOLIN trial (comparing obinutuzumab plus bendamustine to bendamustine alone in rituximab-refractory relapsed FL) confirmed the preclinical predictions of improved efficacy in the face of overt rituximab resistance (Cheson et al, 2016) . Therefore, it might be reasonable to hypothesize that this agent will also prove an attractive option at relapse. This question will hopefully be addressed in ongoing head-to-head clinical trials (Table IV) .
The CLL-11 trial demonstrated a clear advantage of obinutuzumab over rituximab, with prolonged PFS and a higher proportion of patients achieving MRD negativity (Goede et al, 2014) . There is a wealth of pre-clinical data to help explain its activity in the setting of CLL and its ability to overcome particular mechanisms of resistance. Obinutuzumab appears capable of augmenting ADCC despite the known NK cell dysfunction in CLL patients (Le Garff-Tavernier et al, 2011; Rafiq et al, 2013) . By not activating complement, there is less complement-dependent inhibition of NK cells, and CLL cells are also known to express complement inhibitory proteins (Golay et al, 2000 (Golay et al, , 2001 Wang et al, 2008; Ge et al, 2011) . The increased affinity for FCGR3A overcomes the effect of both the low affinity polymorphism of this receptor and also compensates for inhibitory KIR/HLA interactions, with global improvement in ADCC (M€ ossner et al, 2010; Terszowski et al, 2014) . The pronounced cytokine release, in particular interleukin 8, appears to amplify ADCC in CLL patients (Laprevotte et al, 2013; Freeman et al, 2015) . Finally, obinutuzumab causes less trogocytosis -limiting the impact of further decrease in CD20 expression by CLL cells, which already have low density expression, as previously discussed (Herter et al, 2013a; Ysebaert et al, 2015; Valgardsdottir et al, 2017) . Trials evaluating obinutuzumab combinations with alternative agents in a broader population of patients with CLL are already underway (Table IV) . Preliminary results with ibrutinib and venetoclax have been promising (Davids et al, 2017; Flinn et al, 2017; Jain et al, 2017; Michallet et al, 2017; Rogers et al, 2017) and it will be interesting to see if these advantages continue to translate into clinical superiority over rituximab (Table IV) .
An alternative anti-CD20 mAb, ofatumumab, has also performed well in patients with CLL unfit for fludarabine in the up-front setting. When combined with oral chlorambucil, patients randomized to the ofatumumab-containing arm had a median PFS of 22.4 months, as compared to 13.1 months for the chlorambucil only arm (P < 0.0001) (Hillmen et al, 2015) . The combination is approved for this patient population, similar to those enrolled in the CLL-11 trial, although it may not be as cost-effective as the G-CLB comparator (Reyes et al, 2014) . Designed to have greater recruitment of complement-mediated cytotoxicity (Teeling et al, 2006) , a proposed advantage of ofatumumab might be in patients with a deficient effector response -those who are multiply pre-treated or with refractory disease. However, a recent meta-analysis failed to find an advantage of ofatumumab in relapsed/refractory CLL compared with non-ofatumumab regimens (Wu et al, 2017) . Similarly, no differences were seen in patients with relapsed DLBCL treated with DHAP (dexamethasone, high-dose cytarabine, cisplatin) salvage and either ofatumumab or rituximab (Imhoff et al, 2017) , and a trial of patients with relapsed indolent lymphoma comparing ofatumumab with rituximab was terminated early because of futility (Maloney et al, 2016) .
For patients with de novo DLBCL, the potential advantages of obinutuzumab over rituximab may be less important. Lower affinity polymorphism of the FCGR3A was not convincingly associated with inferior outcomes in DLBCL, with no differences observed in EFS or OS in R-CHOP treated patients (Kim et al, 2006; V ar oczy et al, 2012) . In vivo experiments using aggressive B cell lines in mice have suggested that the direct induction of apoptosis makes a limited contribution to cytotoxicity, so the improved DCD capabilities of obinutuzumab may be less relevant (Beers et al, 2010) . Effector NK cells in DLBCL patients express lower levels of CD16 (FCGR3A) and display reduced degranulation -so the innate effector cell dysfunction in DLBCL may be more challenging to overcome (Challa-Malladi et al, 2011; Danielou-Lazareth et al, 2013) . Interestingly, patients with lower circulating NK cells at baseline treated on the GOYA study had more advanced disease at presentation and appeared to do worse with either CD20-containing regimen (Klanova et al, 2017) . The benefit of improved ADCC or ADP may also prove less pronounced when the tumour is composed of dense sheets of large malignant cells with fewer infiltrating effectors (Gong et al, 2005; Beers et al, 2010) . Exploratory sub-analysis of the GOYA trial did suggest a marginal advantage, although not statistically significant, in patients with the germinal centre B cell (GCB) subtype of DLBCL (3-year PFS 79% G-CHOP versus 71% R-CHOP, HR 0.72 95% CI 0.51-1.03) (Vitolo et al, 2016 . Interestingly, a more recently described subgroup of patients with molecular features similar to FL, referred to "strong-GCB" which made up 25% of the trial population, in which obinutuzumab appeared to confer particular benefit with 3-year PFS estimates of 66% for R-CHOP and 88% for G-CHOP (HR 0.33, 95% CI 0.18-0.63, P = 0.0007) with similar improvements in EFS and OS observed . Perhaps in this particular subgroup of patients, or in other subgroups, such as those with higher numbers of tumour-associated macrophages, reduced tumour expression of CD47 or other relevant biomarkers, directed investigation might prove worthwhile (Chao et al, 2010; Kridel et al, 2015; Riihij€ arvi et al, 2015) . So where does this leave the practicing oncologist? Based on the available evidence, obinutuzumab appears to offer an advantage over rituximab when combined with chlorambucil in patients with untreated CLL and co-morbidities that are unsuitable for fludarabine-based therapy. It has been approved and found to be cost-effective when compared to R-CLB in a number of countries (Becker et al, 2016; Blommestein et al, 2016; Casado et al, 2016; Paquete et al, 2017; Sinha & Redekop, 2018) . Competition will shortly arise from ibrutinib monotherapy in this same patient population, however this agent remains too costly for many payers for use in the upfront setting (Sinha & Redekop, 2018) .
In symptomatic advanced-stage treatment na€ ıve FL, both the European Medicines Agency and the FDA have approved the use of obinutuzumab with chemotherapy followed by maintenance. Globally, the clinical benefits will need to be weighed against somewhat higher toxicity and additional cost. In the United Kingdom, combination was deemed insufficiently cost-effective by the National Institute of Clinical Excellence (NICE) to endorse its use in the upfront setting, at least at the present time (NICE, 2017) .
While benefit in DLBCL has not been demonstrated, given the heterogeneity in this disease entity, whether targeting subgroups such as the "strong-GCB" cohort may preferentially benefit is intriguing, but will require further investigation. The role of obinutuzumab in other aggressive CD20 + malignancies, such as mantle cell and Burkitt lymphoma in addition to B cell acute lymphoblastic leukaemia, is still under investigation. Given its activity in the rituximab-refractory setting, as well as its ability to induce higher rates of MRD-negativity, further evaluation of obinutuzumab in the salvage setting or in combination with synergistic agents in the context of MRD-guided approaches would certainly appear warranted.
